ZOMEDICA CORP (ZOM) Stock Price, Forecast & Analysis

NYSEARCA:ZOM • CA98980M1095

0.0973 USD
0 (-0.21%)
Last: Mar 4, 2025, 08:08 PM

ZOM Key Statistics, Chart & Performance

Key Statistics
Market Cap95.35M
Revenue(TTM)26.73M
Net Income(TTM)-62.19M
Shares979.95M
Float961.51M
52 Week High0.2
52 Week Low0.09
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.03
PEN/A
Fwd PEN/A
Earnings (Next)05-07
IPO2013-10-28
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
ZOM short term performance overview.The bars show the price performance of ZOM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

ZOM long term performance overview.The bars show the price performance of ZOM in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of ZOM is 0.0973 USD. In the past month the price decreased by -19.59%. In the past year, price decreased by -30.94%.

ZOMEDICA CORP / ZOM Daily stock chart

ZOM Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
ZOM Full Technical Analysis Report

ZOM Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ZOM. While ZOM has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ZOM Full Fundamental Analysis Report

ZOM Financial Highlights

Over the last trailing twelve months ZOM reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -57.89% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -29.05%
ROE -30.66%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-900%
Sales Q2Q%10.29%
EPS 1Y (TTM)-57.89%
Revenue 1Y (TTM)11.33%
ZOM financials

ZOM Forecast & Estimates

5 analysts have analysed ZOM and the average price target is 0.26 USD. This implies a price increase of 162.08% is expected in the next year compared to the current price of 0.0973.

For the next year, analysts expect an EPS growth of -110.78% and a revenue growth 10.67% for ZOM


Analysts
Analysts80
Price Target0.26 (167.21%)
EPS Next Y-110.78%
Revenue Next Year10.67%
ZOM Analyst EstimatesZOM Analyst Ratings

ZOM Ownership

Ownership
Inst Owners9.39%
Ins Owners0.74%
Short Float %N/A
Short RatioN/A
ZOM Ownership

ZOM Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.54195.084B
ISRG INTUITIVE SURGICAL INC49.31177.398B
SYK STRYKER CORP25.15142.513B
BSX BOSTON SCIENTIFIC CORP21.29112.294B
BDX BECTON DICKINSON AND CO11.7751.988B
IDXX IDEXX LABORATORIES INC42.950.364B
EW EDWARDS LIFESCIENCES CORP26.8345.797B
GEHC GE HEALTHCARE TECHNOLOGY16.7737.832B
RMD RESMED INC21.137.336B
DXCM DEXCOM INC28.9428.187B

About ZOM

Company Profile

ZOM logo image Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 144 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.

Company Info

ZOMEDICA CORP

100 Phoenix Drive, Suite 125

Ann Arbor MICHIGAN 48108 US

CEO: Robert Cohen

Employees: 144

ZOM Company Website

ZOM Investor Relations

Phone: 17343692555

ZOMEDICA CORP / ZOM FAQ

Can you describe the business of ZOMEDICA CORP?

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 144 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.


Can you provide the latest stock price for ZOMEDICA CORP?

The current stock price of ZOM is 0.0973 USD. The price decreased by -0.21% in the last trading session.


Does ZOM stock pay dividends?

ZOM does not pay a dividend.


How is the ChartMill rating for ZOMEDICA CORP?

ZOM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What do analysts say about ZOMEDICA CORP (ZOM) stock?

5 analysts have analysed ZOM and the average price target is 0.26 USD. This implies a price increase of 162.08% is expected in the next year compared to the current price of 0.0973.


How many employees does ZOMEDICA CORP have?

ZOMEDICA CORP (ZOM) currently has 144 employees.